Close
05-22

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celart

Inicio Anterior 8 9 10 11 Cola

10 Artículos por página (Página 11 / 11) Total de 104 Artículos

© Derechos de autor 2009-2020 Noticias empresariales europeas      Contáctanos   SiteMap